Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis - PubMed (original) (raw)

Comparative Study

. 2009 Nov;53(11):4809-15.

doi: 10.1128/AAC.00269-09. Epub 2009 Aug 24.

Affiliations

• PMID: 19704123
• PMCID: PMC2772351
• DOI: 10.1128/AAC.00269-09

Comparative Study

Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis

Juliet E Foweraker et al. Antimicrob Agents Chemother. 2009 Nov.

Abstract

Multiresistant Pseudomonas aeruginosa isolates can chronically infect patients with cystic fibrosis. Acute infective exacerbations are treated with combinations of two antipseudomonal antibiotics. Patients may respond clinically even if the bacteria are resistant, possibly due to antimicrobial synergy. The challenge for testing for synergy in vitro is that there is no standardized method, and the antibiotic susceptibility in a population of P. aeruginosa isolates in a single sputum sample can vary. We therefore compared (i) antibiotic combinations with different examples of resistant bacteria from the same sputum sample and (ii) the results of synergy testing by different methods. Antibiotic synergy was tested by using resistant P. aeruginosa isolates recovered from sputum samples taken just before the start of treatment for an acute infective exacerbation. Several examples of each morphotype of P. aeruginosa were tested by cidal checkerboard, time-kill curve, and multiple-combination bactericidal testing. The isolates were typed by pulsed-field gel electrophoresis (PFGE). The results were compared with the clinical and microbiological responses to 14 days of antibiotic treatment. Forty-four resistant isolates from nine patients were tested. Some P. aeruginosa isolates with the same morphotype and PFGE pulsotype had different results by synergy testing. There was a poor correlation between the results of the different methods of synergy testing, and no one method would have predicted the response to treatment in all patients. The in vitro effects of antibiotic combinations against different isolates from the same sputum sample can vary, and the results depend on the methodology used. The role of combination testing for the treatment of antibiotic-resistant P. aeruginosa in acute exacerbations of chronic infection in patients with cystic fibrosis needs to be reviewed.

PubMed Disclaimer

Similar articles

• Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients.
  Balke B, Hogardt M, Schmoldt S, Hoy L, Weissbrodt H, Häussler S. Balke B, et al. Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):25-30. doi: 10.1007/s10096-005-0076-9. Eur J Clin Microbiol Infect Dis. 2006. PMID: 16402226
• Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
  Smith S, Ratjen F, Remmington T, Waters V. Smith S, et al. Cochrane Database Syst Rev. 2020 May 15;5(5):CD006961. doi: 10.1002/14651858.CD006961.pub5. Cochrane Database Syst Rev. 2020. PMID: 32412092 Free PMC article.
• Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
  Waters V, Ratjen F. Waters V, et al. Cochrane Database Syst Rev. 2017 Jun 19;6(6):CD006961. doi: 10.1002/14651858.CD006961.pub4. Cochrane Database Syst Rev. 2017. PMID: 28628280 Free PMC article. Updated. Review.
• Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
  Waters V, Ratjen F. Waters V, et al. Cochrane Database Syst Rev. 2015 Nov 2;(11):CD006961. doi: 10.1002/14651858.CD006961.pub3. Cochrane Database Syst Rev. 2015. PMID: 26522473 Updated. Review.
• Combination antibiotic susceptibility of biofilm-grown Burkholderia cepacia and Pseudomonas aeruginosa isolated from patients with pulmonary exacerbations of cystic fibrosis.
  Dales L, Ferris W, Vandemheen K, Aaron SD. Dales L, et al. Eur J Clin Microbiol Infect Dis. 2009 Oct;28(10):1275-9. doi: 10.1007/s10096-009-0774-9. Epub 2009 Jul 3. Eur J Clin Microbiol Infect Dis. 2009. PMID: 19575248

Cited by

• Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems.
  Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Høiby N, Moskowitz SM. Gutu AD, et al. Antimicrob Agents Chemother. 2013 May;57(5):2204-15. doi: 10.1128/AAC.02353-12. Epub 2013 Mar 4. Antimicrob Agents Chemother. 2013. PMID: 23459479 Free PMC article.
• PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.
  Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Høiby N, Moskowitz SM. Miller AK, et al. Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9. doi: 10.1128/AAC.05391-11. Epub 2011 Oct 3. Antimicrob Agents Chemother. 2011. PMID: 21968359 Free PMC article.
• Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
  Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, Katz MF, Ahrens R, Hornick D, Joseph PM, Gibson RL, Aitken ML, Benton WW, Burns JL. Moskowitz SM, et al. Pediatr Pulmonol. 2011 Feb;46(2):184-92. doi: 10.1002/ppul.21350. Epub 2010 Oct 20. Pediatr Pulmonol. 2011. PMID: 20963843 Free PMC article. Clinical Trial.
• Epidemiology, Biology, and Impact of Clonal Pseudomonas aeruginosa Infections in Cystic Fibrosis.
  Parkins MD, Somayaji R, Waters VJ. Parkins MD, et al. Clin Microbiol Rev. 2018 Aug 29;31(4):e00019-18. doi: 10.1128/CMR.00019-18. Print 2018 Oct. Clin Microbiol Rev. 2018. PMID: 30158299 Free PMC article. Review.
• Heterogenous Susceptibility to R-Pyocins in Populations of Pseudomonas aeruginosa Sourced from Cystic Fibrosis Lungs.
  Mei M, Thomas J, Diggle SP. Mei M, et al. mBio. 2021 May 4;12(3):e00458-21. doi: 10.1128/mBio.00458-21. mBio. 2021. PMID: 33947755 Free PMC article.

References

1. 1. Aaron, S. D., D. Kottachchi, W. J. Ferris, K. L. Vandemheen, M. L. St. Denis, A. Plouffe, S. P. Doucette, R. Saginur, F. T. Chan, and K. Ramotar. 2004. Sputum versus bronchoscopy for diagnosis of Pseudomonas aeruginosa biofilms in cystic fibrosis. Eur. Respir. J. 24:631-637. - PubMed
2. 1. Aaron, S. D., K. L. Vandemheen, W. Ferris, D. Fergusson, E. Tullis, D. Haase, Y. Berthiaume, N. Brown, P. Wilcox, V. Yozghatlian, P. Bye, S. Bell, F. Chan, B. Rose, A. Jeanneret, A. Stephenson, M. Noseworthy, A. Freitag, N. Paterson, S. Doucette, C. Harbour, M. Ruel, and N. MacDonald. 2005. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 366:463-471. - PubMed
3. 1. Andrews, J. M. 2001. Determination of minimum inhibitory concentrations. J. Antimicrob. Chemother. 48(Suppl. 1):5-16. - PubMed
4. 1. Anonymous. 2002. Antibiotic treatment for cystic fibrosis. Report of the United Kingdom Cystic Fibrosis Trust's Antibiotic Group, 2nd ed. Cystic Fibrosis Trust, Bromley, United Kingdom.
5. 1. Balke, B., M. Hogardt, S. Schmoldt, L. Hoy, H. Weissbrodt, and S. Haussler. 2006. Evaluation of the E test for the assessment of synergy of antibiotic combinations against multiresistant Pseudomonas aeruginosa isolates from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 25:25-30. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Medical

  • Genetic Alliance
  • MedlinePlus Health Information